• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
DeviceUROVYSION BLADDER CANCER KIT
Classification Nametest, fluorescence in situ hybridization (fish), for bladder cancer detection and monitoring for recurrence
Generic Nametest, fluorescence in situ hybridization (fish), for bladder cancer detection and monitoring for recurrence
Applicant
ABBOTT MOLECULAR
1300 e. touhy avenue
des plaines, IL 60018
PMA NumberP030052
Supplement NumberS011
Date Received01/16/2013
Decision Date02/10/2013
Product Code
NSD[ Registered Establishments with NSD ]
Advisory Committee Pathology
Supplement Type30-day notice
Supplement Reason process change - manufacturer/sterilizer/packager/supplier
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Addition of an alternate supplier for human placental (hp) dna which is a component of the pathvysion her-2 dna probe kit and the urovysion bladder cancer kit.
-
-